BioCryst Pharmaceuticals Shares Rise 10.7% After Earnings Beat

The biotech company reported better-than-expected Q4 results, sending its stock higher.

Published on Feb. 27, 2026

Got story updates? Submit your updates here. ›

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) saw its shares rise 10.7% during mid-day trading on Friday after the company reported Q4 earnings that exceeded analyst expectations. The biotechnology company posted earnings per share of $1.12, topping the consensus estimate of $0.07, while revenue came in at $163.28 million, higher than the expected $151.32 million.

Why it matters

BioCryst's strong quarterly performance reflects the continued success of its lead drug Orladeyo, an oral treatment for hereditary angioedema (HAE). The company's ability to exceed expectations on both the top and bottom lines suggests its HAE franchise is gaining traction and could bode well for future growth.

The details

BioCryst reported a net loss of $1.46 million, or a negative margin of 1.46%, for the quarter. However, the company's revenue surged 209.1% year-over-year, driven by increased Orladeyo sales. The drug was approved in the U.S. and Europe for the prophylactic treatment of HAE.

  • BioCryst reported its Q4 2025 earnings on February 27, 2026.

The players

BioCryst Pharmaceuticals, Inc.

A clinical-stage biotechnology company focused on the discovery and development of novel, oral small-molecule medicines for rare and serious diseases.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

The takeaway

BioCryst's strong Q4 performance underscores the growing demand for its HAE treatment Orladeyo, which could drive further growth for the company as it continues to expand its commercial footprint and pipeline of rare disease therapies.